Clinical Research Directory

Inclusion Criteria: * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study. * Ability to take oral medication and be willing to adhere to the study regimen. * Male age \>18 years. * Histologically confirmed prostate cancer. * Currently receiving gonadotropin releasing hormone agonist/antagonist monotherapy. * Serum testosterone \<50 ng/dL. * Serum AST and ALT less than 2 times upper limit of normal. * Endorsed reduced sexual interest. * Attempted intercourse. * Current sexual partner. * Was sexually active with partner within 6 months prior to ADT. * No other antineoplastic therapy planned during study period. * No active symptoms attributable to systemic prostate cancer. Exclusion Criteria: * Current systemic prostate cancer treatment besides GnRH agonist/antagonist, anti-androgens, or abiraterone. * Prior to ADT had erections not firm enough for intercourse despite use of pharmacologic agents such as phosphodiesterase-5 inhibitors. * Current symptoms attributable to active prostate cancer * Moderate or heavy alcohol use (\>2 drinks/day) * Concurrent moderate or strong CYP3A4 inhibitors * Concurrently taking medication classified as a monoamine oxidase inhibitor.